Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Paclitaxel + Pertuzumab + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Pertuzumab | Perjeta | 2C4 Antibody | HER2 (ERBB2) Antibody 76 | Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov). |
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02344472 | Phase III | Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab Capecitabine + Pertuzumab + Trastuzumab Exemestane + Pertuzumab + Ribociclib + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Eribulin + Pertuzumab + Trastuzumab Anastrozole + Pertuzumab + Ribociclib + Trastuzumab Goserelin + Pertuzumab + Ribociclib + Trastuzumab Pertuzumab + Trastuzumab + Vinorelbine Nab-paclitaxel + Pertuzumab + Trastuzumab Leuprolide + Pertuzumab + Ribociclib + Trastuzumab | Detect V / CHEVENDO (Chemo vs. Endo) | Active, not recruiting | DEU | 0 |
NCT04301375 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine | Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS) | Not yet recruiting | ESP | 0 |
NCT03747120 | Phase II | Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | Active, not recruiting | USA | 0 |
NCT01855828 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT03716180 | Phase I | Paclitaxel + Pertuzumab + Trastuzumab | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | Active, not recruiting | USA | 0 |
NCT03412643 | Phase II | Cyclophosphamide + Doxorubicin Paclitaxel + Pertuzumab + Trastuzumab | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12) | Recruiting | USA | 0 |
NCT03726879 | Phase III | Cyclophosphamide + Doxorubicin Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) | Completed | USA | POL | ITA | ESP | DEU | CZE | CAN | BRA | 4 |
NCT06439693 | Phase II | Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan Nab-paclitaxel + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab + Tucatinib Ado-trastuzumab emtansine + Tucatinib | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT03199885 | Phase III | Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | Active, not recruiting | USA | CAN | 0 |
NCT01276041 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab | Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT01730833 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | Active, not recruiting | USA | 0 |
NCT01847001 | Phase II | Propranolol Paclitaxel + Pertuzumab + Trastuzumab | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | Completed | USA | 0 |
NCT04784715 | Phase III | Pertuzumab + Trastuzumab deruxtecan Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Active, not recruiting | USA | TUR | SWE | ROU | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | ARG | 11 |
NCT04266249 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine Docetaxel + Pertuzumab + Trastuzumab Nab-paclitaxel + Pertuzumab + Trastuzumab | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | Recruiting | USA | 1 |
NCT04425018 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Margetuximab-cmkb + Paclitaxel + Pertuzumab | MARGetuximab Or Trastuzumab (MARGOT) (MARGOT) | Active, not recruiting | USA | 0 |
NCT01817452 | Phase II | Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT) | Active, not recruiting | DEU | 0 |
NCT03644186 | Phase II | Letrozole + Palbociclib + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH) | Completed | ITA | FRA | CHE | BEL | 0 |
NCT03498521 | Phase II | Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | Active, not recruiting | TUR | ROU | POL | NOR | NLD | LVA | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | BRA | BGR | AUT | AUS | 8 |